SUPN Supernus Pharmaceuticals Inc.

36.75
+0.12  (+0%)
Previous Close 36.63
Open 36.66
Price To Book 4.55
Market Cap 1920445228
Shares 52,257,013
Volume 944,316
Short Ratio
Av. Daily Volume 589,929

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 3 data from two of its trials in children released December 6, 2018 met primary endpoints but with concerns regarding effect size vs competition. Data from first adolescent trial due by the end of December 2018 while data from the second trial are due 1Q 2019.
SPN-812
ADHD
Phase 3 data due mid-2019
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy

Latest News

  1. Should You Be Worried About Insider Transactions At Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)?
  2. Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call
  3. See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
  4. An Intrinsic Calculation For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shows It’s 45.76% Undervalued
  5. 3 Top Small-Cap Stocks to Buy Right Now
  6. MYL vs. SUPN: Which Stock Is the Better Value Option?
  7. Does Market Volatility Impact Supernus Pharmaceuticals, Inc.’s (NASDAQ:SUPN) Share Price?
  8. Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT
  9. Supernus to Present at the 2019 J.P. Morgan Healthcare Conference
  10. Supernus Pharma's ADHD drug meets main goal in study on adolescents
  11. Hedge Funds Aren’t Crazy About Supernus Pharmaceuticals Inc (SUPN) Anymore
  12. Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
  13. Why We Think Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Could Be Worth Looking At
  14. Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy
  15. 3 Top Biotech Stocks to Buy in December
  16. This Index Of Leading Stocks Falls Into A Bear Market As Boeing Stings Dow Jones
  17. Supernus Pharma's ADHD treatment fails to impress; shares fall

SEC Filings

  1. 8-K - Current report 19598454
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583147
  3. 8-K - Current report 19568385
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19520865
  5. 8-K - Current report 181250011
  6. 8-K - Current report 181243855
  7. 8-K - Current report 181227032
  8. UPLOAD [Cover] - SEC-generated letter
  9. CT ORDER - Confidential treatment order 181210150
  10. CORRESP [Cover] - Correspondence